Navigation Links
Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
Date:9/30/2009

repeated injections.

About ITCA 650

ITCA 650 therapy for type 2 diabetes consists of DUROS continuous delivery of exenatide. The DUROS delivery technology comprises the patented DUROS device, a matchstick-size miniature osmotic pump that is inserted subcutaneously to provide continuous and consistent drug therapy, and proprietary formulation technology that maintains stability of therapeutic proteins and peptides at human body temperature for extended periods of time. The DUROS technology can deliver up to a full year of therapy from a single ITCA 650 insertion. Unlike other extended delivery technologies, such as polymers or albumin fusions, DUROS delivery allows for steady-state drug delivery upon insertion and near immediate withdrawal of therapy to manage side effects, if required. Exenatide, the active agent in ITCA 650, has been approved in the US, Europe and many other markets and is currently marketed as a twice-daily self-injection therapy for type 2 diabetes.

About Intarcia

Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to ensure enhanced treatment outcome by optimizing patient adherence and improving the convenience and tolerability of drug therapies. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above body temperature and to deliver them in a constant and consistent manner via the proprietary DUROS drug delivery platform. Intarcia is pursuing clinical stage development programs for type 2 diabetes and hepatitis C.

Intarcia and its logo are registered trademarks of Intarcia Therapeutics, Inc. DUROS is a registered trademark of ALZA Corporation licensed to Intarcia Therapeutics, Inc. in certain fields. Byetta is a registered trademark of Amylin Pharmaceuticals, Inc.

    MEDIA CONTACT
    Intarcia:
    James Ahlers
    Intarcia Therapeutics, Inc.
    (510)782-7800
    <
'/>"/>
SOURCE Intarcia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
2. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
5. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
6. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
7. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
8. Nile Therapeutics, Inc. Adds to Executive Management Team
9. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
10. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
11. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... PROVIDENCE, N.J. , Sept. 2, 2014   ... for MassBio,s 20th Annual Golf Classic, a major fundraiser ... event will be held on September 5 at the ... . The MassBioEd Foundation supports ... through educational programs, workforce development, and lifelong learning. ...
(Date:9/2/2014)... nanowires could be used for detailed studies of what ... important for pharmaceuticals research, among other applications. A group ... to make artificial cell membranes form across a large ... All communication between the interior of a cell and ... membrane is a surface layer that holds the cell ...
(Date:9/2/2014)... -- Persistence Market Research ( http://www.persistencemarketresearch.com/ ) ... and Life Sciences: North America ... market for pharmaceutical, biopharma and life sciences is estimated at ... grow at a CAGR of 9.1% from 2014 to ... million in 2019. Browse the full Global ...
(Date:9/2/2014)... 2014 Myriant Corporation, a global ... a distribution agreement with Azelis Group, a specialty ... bio-succinic acid in the Nordics, Benelux, France, Iberia, ... in the industrial and base chemicals markets. , ... a far-reaching chemical portfolio with extensive distribution networks ...
Breaking Biology Technology:Linde helps fund STEM education in Massachusetts 2Linde helps fund STEM education in Massachusetts 3Nano-forests to reveal secrets of cells 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2
... N.J., June 12 BioNeutral announced today the,results ... anthrax,spores on contact. This chemical technology is designed ... in conjunction with any suspected anthrax,exposure. "The Ygiene(TM) ... in as little as 15 seconds," said Dr. ...
... June 12 GenVault Corporation today,announces Paul J. ... Inc.,has joined its Board of Directors. Mr. Mirabella ... imaging with GE Healthcare where he held,leadership roles ... this substantial background in diagnostics and the healthcare,market, ...
... BRUNSWICK, N.J., June 12 Senesco,Technologies, Inc. ("Senesco" ... announced,that the Company will be presenting at the ... Annual International Convention,which is being held at the ... Galton, Chief Executive Officer of Senesco, will deliver ...
Cached Biology Technology:BioNeutral Announces a BREAKTHROUGH in the Fight Against Bioterrorism 2Paul J. Mirabella, President and CEO of Naviscan PET Systems Inc., Joins GenVault's Board of Directors 2Senesco Technologies to Present at BIO 2008 Business Forum 2
(Date:9/2/2014)... always true that digital distribution of media will ... means, at least when file sizes are large. ... in Yale,s Journal of Industrial Ecology ... for consoles such as PlayStation3. Researchers found that ... greenhouse gas emissions than game files downloaded over ...
(Date:9/2/2014)... New research suggests that professional baseball pitchers with poor ... days in a single season because of injury than are ... back and pelvis. , In the study, 347 pitchers were ... tilt in their pelvis as they raised a leg to ... miss at least 30 days cumulative, not consecutive ...
(Date:9/2/2014)... A new study published in the September issue ... , identifies a novel strategy to diagnose the ... before irreversible structural damage has occurred. This advance ... diabetes on the endothelium of retinal vessels. Using ... to distinguish the early molecular development of diabetic ...
Breaking Biology News(10 mins):In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2
... presents research on the genetic make-up and biology of ... better diagnosis and treatment of the diarrhea disease giardiasis, ... may also bring an understanding of several vital biological ... parasite that exists all over the world and causes ...
... GMES Programme approved the transition to Phase-2 of Segment ... of the programme by the ESA Council at ministerial ... 2 of 116%, giving a total amount of 500 ... ESA to confirm the development of the first three ...
... Now Fully Supports M2SYS Fingerprint Technology to ... Accurately Verify Check Casher Identity, ... biometric,technology research and development firm, announced today its partnership,with ... solutions, to integrate the M2SYS Bio-Plugin(TM) fingerprint,solution into TeraCash, ...
Cached Biology News:New Swedish research hope for millions of sufferers 2M2SYS Technology Partners with TeraCorp Enterprises to Provide Added Security Within Check Cashing Solution 2
... is a simple, easy to use ... bacterial and yeast applications. The ... voltages and either one mm, two ... pressing the pulse button the electroporator ...
... CGH Genomic Labeling Systems are a high-performance ... genomic DNA samples for array-based Comparative Genomic ... direct labeling formats, the BioPrime Plus Array ... solution to your genomic labeling needs. ...
MOUSE ANTI GTP BINDING PROTEIN...
The Cellject Elecroporator is suitable for all cell types including embryo, mammalian, plant, yeast and bacterial. Its has highly user-freindly programing and can be used remotely, for example in a l...
Biology Products: